Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors
Author:
Publisher
Elsevier BV
Subject
Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference104 articles.
1. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer;Guarneri;Cancer Treat Rev,2010
2. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review;Dawood;J Clin Oncol,2010
3. Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2014;(6):CD006242. doi:CD006242.
4. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;Swain;N Engl J Med,2015
5. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016;Deluche;Eur J Cancer,2020
Cited by 40 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Machine learning and bioinformatic analyses link the cell surface receptor transcript levels to the drug response of breast cancer cells and drug off-target effects;PLOS ONE;2024-02-02
2. Immunohistochemistry-derived subtypes of breast cancer distribution in four regions of Ethiopia;Frontiers in Endocrinology;2023-11-09
3. Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer;JNCI: Journal of the National Cancer Institute;2023-09-07
4. Disitamab Vedotin, a HER2-directed Antibody Drug-Conjugate, in Patients with HER2- positive and HER2-low Advanced Breast Cancer:A Phase 1/1b Study;2023-09-06
5. Inetetamab in combination with rapamycin and chemotherapy for trastuzumab‐treated metastatic human epidermal growth factor receptor 2‐positive breast cancer with abnormal activation of PI3K/Akt/mTOR pathway;Cancer Reports;2023-07-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3